Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer files suit against J&J over Remicade contracts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2017 | 09:24pm CEST
The Pfizer logo is seen at their world headquarters in New York

Drugmaker Pfizer Inc (>> Pfizer) on Wednesday filed a lawsuit against Johnson & Johnson (>> Johnson & Johnson), saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Drugmaker Pfizer Inc (>> Pfizer) on Wednesday filed a lawsuit against Johnson & Johnson (>> Johnson & Johnson), saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Pfizer said in the suit that J&J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer's drug from insurance coverage, keeping it out of the hands of patients.

J&J said in an e-mailed statement that the lawsuit was without merit and that the company is competing on value and price.

"To date Pfizer has failed to demonstrate sufficient value to patients, providers, payers and employers," said Scott White, President of Janssen Biotech Inc, a unit of J&J.

J&J signed exclusionary contracts with health insurers, hospitals and doctor groups after U.S. regulators approved it as a reasonable substitute for Remicade in 2016, Pfizer said.

The contracts with insurers - including UnitedHealth Group (>> UnitedHealth Group), Anthem Inc (>> Anthem Inc), Aetna Inc (>> Aetna Inc) and Cigna Corp (>> CIGNA Corporation) - covered about 70 percent of the commercially insured patients in the United States, the lawsuit said.

Both Aetna and Anthem declined to comment. Other U.S. insurers contacted for this story did not have an immediate comment.

Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the suit. Its Inflectra rival is priced 19 percent lower than that list price.

But Pfizer said it has not been able to reach customers because of J&J's anticompetitive actions. The suit comes at a time when insurers, consumers and the U.S. government have pushed for lower drug prices, saying double-digit annual price increases are unsustainable.

Biosimilars are intended to be lower cost alternatives to expensive biotech medicines. But because they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be.

Pfizer said in the lawsuit that J&J's contracts with many insurers exclusively pay for Remicade and only pay for Inflectra in limited cases where patients "fail first" on Remicade.

In return, Pfizer said, J&J pays after-market rebates on both new and existing customers' Remicade purchases. To make up for the J&J rebates and discounts on this large base of old and new customers, Pfizer said it would need to price Inflectra below its own average variable cost.

Pfizer shares were up 1.3 percent, or 45 cents, at $35.90 and J&J shares fell 1.6 percent, or $2.10, to $133.11.

The case was filed in the U.S. District Court for the Eastern District of Pennsylvania.

(Reporting by Caroline Humer in New York and Divya Grover in Bengaluru; editing by Sriraj Kalluvila, Nick Zieminski and G Crosse)

By Caroline Humer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:17a Healthcare looking in good shape
10/19 JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. Food and Drug A..
10/19 JOHNSON & JOHNSON : The Fastest Growing Regions for Dermatological Drug Sales Ar..
10/19 JOHNSON & JOHNSON : Missouri court throws out $72M million verdict in Johnson & ..
10/19 JOHNSON & JOHNSON : Looking back on Black Monday, the stock market crash of 1987
10/19 Genmab Announces Net Sales of DARZALEX for Third Quarter of 2017
10/19 JOHNSON & JOHNSON : and Reports 2017 Third Quarter Results
10/19 ENDOLOGIX, INC. (NASDAQ : ELGX) Files An 8-K Departure of Directors or Certain O..
10/19 JOHNSON & JOHNSON : Earnings Review and Free Research Report: Johnson & Johnson ..
10/19 JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2017
More news
News from SeekingAlpha
10/19 Is It Time To Take Profits On Johnson & Johnson?
10/19 Retiring In Your 50s Might Be Easier Than You Think
10/19 Alcobra up 46% premarket on Arcturus/Janssen deal in HBV
10/19 Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
10/19 Johnson & Johnson to acquire Surgical Process Institute
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,36%
P/E ratio 2017 24,40
P/E ratio 2018 19,86
EV / Sales 2017 5,22x
EV / Sales 2018 4,82x
Capitalization 381 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,3%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924